Not available outside of the UK & Ireland.

Analysis Note

homogeneous by SDS-PAGE

General description

Native fibrinogen from human plasma, depleted of plasminogen using a Lys-agarose column. An acute-phase plasma protein found at about 300 mg/dl. Contains ≥ 95% clottable proteins.

Native fibrinogen from human plasma, depleted of plasminogen using a Lys-agarose column. An acute-phase plasma protein found at about 300 mg/dl. Conversion of soluble fibrinogen to the insoluble clot-forming fibrin is the terminal stage of blood clotting. Clinically, fibrinogen is found at elevated levels during pregnancy, after surgery trauma, or in cases of myocardial infarction. It is found at decreased levels in cases of liver cirrhosis and serum hepatitis. The plasminogen was depleted using a Lys-agarose column.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Wang, H., et al. 1995. J. Infect. Dis.171, 85.

Packaging

500 mg in Glass bottle

Preparation Note

To prevent clot formation, warm the H₂O and the fibrinogen to 37°C prior to dissolution.

Reconstitution

Following reconstitution, aliquot and freeze (-70°C) for long term storage or store at room temperature (20°C) for short-term storage. Stock solutions are stable for up to 4 h at 20°C or for up to 6 months at -70°C. Do not store solutions on ice; precipitation will occur. Stock solutions stored at -70°C should be thawed in a water bath maintained at 37°C.

Warning

Toxicity: Harmful (C)